According to the newly released first edition of Rheumatology Insights, a research-based report published by Cardinal Health Specialty Solutions, surveyed rheumatologists said they plan to hire more advanced practice providers (APPs), expand patient care with telemedicine, and invest in technology to manage the increased demand for services. This is due to a decreasing number of healthcare providers as well as a growing volume of patients.
Based on a survey taken by over 100 U.S. rheumatologists, hiring more APPs (57%) was the most frequently cited solution for managing growing patient demand. Following, the adoption of telemedicine (34%) and investments in other technology (34%) were also cited as potential solutions.
This research was conducted just before the onset of COVID-19 in the U.S., suggesting that rheumatologists were already thinking about more virtual-oriented services like telemedicine even before it became mainstream.
The survey also explored rheumatologists’ attitudes about value-based care and biosimilars. It suggested that rheumatologists are familiar and comfortable with biosimilars, but are also concerned about the economics of prescribing them. They also report positive financial performance under MIPS (Merit-based Incentive Payment System), but remain skeptical about the broader goals of value-based care.
The findings in Rheumatology Insights are based on web-based surveys conducted in February and March 2020. More than 100 rheumatologists from a mix of community- and hospital-based practices participated in the research.
For more information on the full report, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.